Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy(CARTITUDE-5) | active not recruiting | Phase 3 | 743 | Janssen Research & Development, LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313) | active not recruiting |
| Phase 3 |
| 282 |
| Loxo Oncology, Inc.INDUSTRY |
| 20 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT05083169 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-3) | active not recruiting | Phase 3 | 587 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT05438043 | A Study of Daratumumab | active not recruiting | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 17 | Sep 25, 2026 | clinicaltrials |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | active not recruiting | Phase 1 | 196 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05455320 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment(MonumenTAL-3) | active not recruiting | Phase 3 | 864 | Janssen Research & Development, LLCINDUSTRY | 18 | Sep 25, 2026 | clinicaltrials |
| NCT05548062 | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera(Prospero) | active not recruiting | — | 242 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05572229 | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma(IFM2021-01) | active not recruiting | Phase 2 | 74 | University Hospital, LilleOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | active not recruiting | Phase 2 | 47 | Reid Merryman, MDOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05784441 | A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | active not recruiting | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia(TAILOR) | active not recruiting | Phase 2 | 333 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06106360 | A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy | active not recruiting | — | 53 | Inova Health Care ServicesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06139406 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer | active not recruiting | Phase 1 | 70 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06169215 | Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide(MonumenTAL-6) | active not recruiting | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06284122 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5(MorningLyte) | active not recruiting | Phase 3 | 790 | The Lymphoma Academic Research OrganisationOTHER | 7 | Sep 25, 2026 | clinicaltrials |
| NCT06470438 | A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 58 | Janssen Research & Development, LLCINDUSTRY | 7 | Sep 25, 2026 | clinicaltrials |
| NCT06476665 | A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. | active not recruiting | — | 12 | PfizerINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06550895 | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma(MonumenTAL-8) | active not recruiting | Phase 2 | 11 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06577025 | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma(aMMbition) | active not recruiting | Phase 2 | 43 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT06604715 | A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 17 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06618001 | A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 64 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06660563 | A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) | active not recruiting | Phase 1 | 19 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06910670 | Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid | active not recruiting | N/A | 197 | Washington University School of MedicineOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06929624 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | active not recruiting | Phase 3 | 282 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07266441 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma(TRIlogy-3) | active not recruiting | Phase 2 | 168 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT02940301 | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 18 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02992522 | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 22 | Beth ChristianOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04219163 | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | active not recruiting | Phase 1 | 18 | Baylor College of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 23 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04981899 | A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma(NICE-40) | active not recruiting | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05044039 | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | active not recruiting | Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05552976 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)(SUCCESSOR-2) | active not recruiting | Phase 3 | 606 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 24, 2026 | clinicaltrials |
| NCT02392429 | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03463057 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL(HO151DLBCL) | active not recruiting | Phase 2 | 109 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Sep 23, 2026 | clinicaltrials |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)(BRUIN-MCL-321) | active not recruiting | Phase 3 | 500 | Loxo Oncology, Inc.INDUSTRY | 24 | Sep 23, 2026 | clinicaltrials |
| NCT04732845 | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | active not recruiting | Phase 1 | 18 | Benjamin TomlinsonOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06170671 | REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania(REACH) | active not recruiting | — | 250 | AstraZenecaINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00039676 | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | active not recruiting | — | 1,836 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00352924 | Agriculture Health Study | active not recruiting | — | 89,655 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02537613 | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML) | active not recruiting | Phase 3 | 968 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 15 | Sep 22, 2026 | clinicaltrials |
| NCT05035706 | Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors | active not recruiting | Early Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05201066 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | active not recruiting | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 15 | Sep 22, 2026 | clinicaltrials |
| NCT05231629 | Sequential Therapy in Multiple Myeloma Guided by MRD Assessments(MASTER-2) | active not recruiting | Phase 2 | 300 | University of Alabama at BirminghamOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05471843 | Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 125 | BeOne MedicinesINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT01829958 | Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | active not recruiting | N/A | 201 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 488 | National Cancer Institute (NCI)NIH | 4 | Sep 21, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials